A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors

To be considered for this study, you would need to have certain advanced solid cancers that have progressed despite previous treatments. This usually means your cancer has continued to grow after standard care, or you can't have those treatments for some reason. The research team would need to take fresh tissue samples (biopsies) from your tumor before and during the study for analyses. Importantly, your cancer would need to be visible and measurable on scans, and at least one part of it should be easy to take a biopsy from.

There are also some important reasons why you might not be able to join. For example, if you are pregnant or breastfeeding, or if you have certain active or recent serious health conditions like specific heart problems, uncontrolled autoimmune diseases, or specific lung conditions. If you've had major surgery very recently, or if your cancer has spread to your brain in certain ways, you may also not be able to take part. The study also cannot include individuals who have been treated with certain other therapies too recently or those who have had a severe immune reaction to similar treatments in the past.

If you decide to take part in this study, you would receive the new study medication, BMS-986340, sometimes alone and sometimes combined with other treatments. You would have regular visits to the clinic for check-ups, blood tests, and scans to see how you're responding and to monitor for any side effects. You might need to have new biopsies taken from your tumor during the study. The exact schedule of visits and tests would depend on which part of the study you are in and which treatment group you are assigned to. This study is generally for adults aged 18 and over. The total duration of your participation would be discussed with you by the research team, and it would involve ongoing monitoring and follow-up for a period after you stop taking the treatment.